Heart failure金沙官网平台

金沙国际

金沙官网平台

金沙官网平台

Congestive heart failure, also known as heart failure (HF) is a chronic and progressive disease1 that affects 64 million people worldwide.2 In the US, fifty percent of patients will die within five years of diagnosis,3 and it is becoming noticeably more prevalent with our aging population.4 Heart failure is the leading cause of hospitalisation for those over the age of 65 and also impacts quality of life and overall health outcomes.5,6 Despite medical advances, it remains as life-threatening as some of the most common types of cancer in both men (prostate and bladder cancers) and women (breast cancers).7金沙官网平台

 

Addressing heart failure and other CVRM diseases金沙国际

金沙官网平台

We dare to do things differently and challenge ourselves to better understand how our portfolio can be used to help address multiple risk factors or comorbidities across cardiovascular, renal, metabolic diseases金沙官网平台

 

金沙官网平台

I’ve been having an ache in my chest for 关于 two years. My skin felt tight around my legs, and even my fingers.

View our factsheet on the connection between heart failure and type-2 diabetes

Facing daily life with emotional worry and physical burden金沙国际

Patients suffering from chronic heart failure disease often feel daily activities, including even carrying groceries, are energy-depleting tasks. Alongside the physical challenges heart failure poses, patients may become tormented with worry, as they fear normal tasks could worsen their condition or even threaten their life. To add to patients’ pain, individuals suffering from heart failure may furthermore be impacted by interconnected cardiovascular, renal, or metabolic diseases.17 金沙官网平台

金沙国际

Although life expectancy of heart failure patients improved in the last decades due to advanced treatment options, mortality remains high, even higher than in certain common cancers in both men (prostate and bladder cancers) and women (breast cancers).7,18 In the US, about half of the people diagnosed with chronic heart failure will die within five years from diagnosis, demonstrating the need for improved prevention and treatment measures.3

It is not only our goal to alleviate the persistent feeling of angst which drives HF patients to despair, but to also raise awareness of the importance of warning signs of heart failure, as they can also be a means to detect other interrelated diseases.19, 20

金沙国际

people are impacted by heart failure worldwide2

金沙国际

for those over the age of 65 is heart failure5

金沙国际

chronic heart failure patients who take RAAS inhibitors at some point develop hyperkalaemia15

金沙国际

of people with T2D will develop chronic or acute heart failure21

金沙国际

of both men and women with heart failure has been shown to be lower than some of the most common cancers in both men (prostate and bladder cancers) and women (breast cancers)7 in Scotland7

金沙官网平台

金沙官网平台

金沙官网平台

 

We work with multiple different partners including the European Society of Cardiology (ESC), to sp阅读 knowledge 关于 heart failure as an international health issue. Together with these established partners, we developed a series of 资讯rmative materials, such as 资讯graphics and social media posts, to not only activate new channels to raise awareness to a wider audience, but also re资讯rce heart failure as a global pertinent problem that demands our urgent attention.   

 

金沙官网平台

 

ACT – Accelerate Change Together – on Heart Failure is a cross-functional programme which operates at the country level to achieve healthcare system change. Through the development of localized strategies, ACT on Heart Failure calls for healthcare systems and stakeholders to adopt a more proactive approach to early diagnosis, improved management and, where possible, prevention of heart failure to reduce the risk of hospitalisation and life-threatening events.

金沙官网平台

AstraZeneca has one of the richest clinical pipelines today in the heart failure area in terms of prevention and treatment of various subtypes of heart failure. Our ambition is indeed to eventually reverse the disease and to eradicate heart failure.

Li-Ming Gan Medical Science Director, Early Clinical Development (Cardiovascular and Metabolism), BioPharmaceuticals R&D

金沙国际

SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

View Regina’s profile

金沙国际

Medical Science Director, Early Clinical Development (Cardiovascular and Metabolism), BioPharmaceuticals R&D

View Li-Ming’s profile

金沙官网平台

金沙app旧版

CVRM金沙国际

We aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas.
金沙app下载客户端

Chronic kidney disease金沙国际

We aim to treat life-threatening complications and halt disease progression to provide millions of patients living with chronic kidney disease with a longer and greater quality of life.
金沙官网手机下载app

Metabolism金沙国际

Our focus is to transform the lives of the millions of patients living with metabolic diseases. We aspire to move healthcare professionals to treat beyond HbA1C, prevent early cardiovascular and renal complications and explore non-alcoholic steatohepatitis (NASH).
金沙平台注册

Cardiovascular disease金沙国际

Our ambition is to eliminate the remaining cardiovascular (CV) risk of patients with CV disease and stopping disease progression, therefore preventing CV events from occurring and protecting the lives of millions of patients.

References金沙官网平台

  1. American Heart Association. What is Heart Failure?; 2017 [cited 2019 Sep 5]. Available from: URL: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure.
  2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211-1259.
  3. Mozaffarian D, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360.
  4. Savarese G, et al. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11.
  5. Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11(4):329–37. doi:10.11909/j.issn.1671-5411.2014.04.008
  6. European Society of Cardiology (ESC). One in five people will develop heart failure. ScienceDaily. 2015. Available from: www.sciencedaily.com/releases/2015/05/150505111934.htm [Accessed June 2018].
  7. Mamas MA, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095–104.
  8. Gheorghiade M, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114(11):1202–13.
  9. Faden G, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013;101(3):309-16.
  10. Seferović PM et al. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20(5):853–72.
  11. House AA, et al. Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(6):1304–17.
  12. Segall L, et al. Heart failure in patients with chronic kidney disease: A systematic integrative review. Biomed Res Int. 2014;2014:937398.
  13. National Kidney Foundation. "Clinical Update on Hyperkalemia." 2014. Accessed 16 May 2018. https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf.
  14. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm. 2013 Dec;35(6):1099-104.
  15. Thomsen RW, et al. Elevated Potassium Levels in Patients with Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. J Am Heart Assoc. 2018 May 22;7(11).
  16. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015 Sep;21 (11 Suppl):S212-S220.
  17. Arnold SV, et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab. 2018;20(8):2000–3.
  18. Bytyçi I, Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol. 2015;15(1):63–8.
  19. Lawson CA et al. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 2018; 15(3):e1002540.
  20. American Heart Association. Warning signs of Heart Failure. 2017. Accessed 12 Sept 2019. https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure
  21. Rosano GM, et al. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017;3(1):52-55.

Veeva ID: Z4-20768

Date of preparation: October 2019

Date of expiry: October 2021